SLC5A2 and type 2 diabetes mellitus: Treatment with the SGLT2 inhibitor tofogliflozin significantly decreased blood pressure and normalized circadian rhythms without inducing compensatory changes in heart rate, which may be the source of its beneficial effects on cardiovascular outcome in high-risk patients with T2DM [40].